Research programme: c-Myc translation inhibitors - Anima Biotech
Latest Information Update: 28 Dec 2024
At a glance
- Originator Anima Biotech
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-myc translation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for research development in Cancer in USA
- 02 Dec 2022 Early research is ongoing for Cancer in USA (Anima Biotech pipeline, December 2022)
- 28 Sep 2022 No recent reports of development identified for research development in Cancer in USA